NewAmsterdam Pharma Company NV (NAMS) Q1 2026 Earnings Call Transcript

Why It Matters

These results demonstrate that NewAmsterdam’s cost‑discipline and partnership model are translating into stronger cash generation and market share gains, positioning the company to capitalize on expanding triglyceride‑lowering therapy demand.

Key Takeaways

• Cash $308M, zero debt, strong liquidity.
• US VASCEPA market share 48%, prescriptions +17% YoY.
• Operating loss narrowed to $11.3M, expenses down 31%.
• Europe revenue doubled sequentially, Recordati partnership fuels growth.
• Positive cash flow $6.4M, second consecutive quarter.

Pulse Analysis

NewAmsterdam’s Q1 performance underscores the power of disciplined cost management combined with strategic capital allocation. By trimming operating expenses 31% and reducing SG&A to under half of revenue, the firm turned a $16.8 million loss a year ago into an $11.3 million loss this quarter, while delivering $6.4 million of operating cash. This financial resilience, bolstered by a $308 million cash pile and zero debt, gives the company flexibility to invest in growth initiatives and weather generic pressure in the United States.

In the U.S., VASCEPA continues to dominate the icosapent ethyl market, expanding its share to 48% and lifting prescription volume 17% year‑over‑year. The drug’s momentum is reinforced by the latest ACC/AHA and ESC/EAS guidelines, which uniquely position icosapent ethyl as the only oral triglyceride‑lowering therapy proven to cut cardiovascular events when added to statins. Maintaining payer exclusivity through 2026 further shields revenue streams, allowing NewAmsterdam to sustain profitability despite the entry of authorized generics.

Internationally, the Recordati partnership has transformed the European commercial model, shifting to a supply‑only arrangement that more than doubled Q1 revenue versus the prior quarter. Early shipments to ten European markets and expanding rest‑of‑world collaborations in China, Australia, and the Middle East signal a scalable growth engine. Planned launches in South Korea and Singapore for 2027, coupled with ongoing regulatory filings across Southeast Asia, position NewAmsterdam to capture unmet cardiovascular risk reduction needs globally, while the anticipated $70 million restructuring savings solidify long‑term financial upside.